Ianalumab  (Synonyms: VAY-736)

Ianalumab (VAY-736) is a human, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM)^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

TNFRSF13C/BAFFR/CD268

Ianalumab (0.1 μg/mL; 72 h) shows enhanced ADCC and cytokine production induction by chronic lymphocytic leukemia (CLL) NK cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ianalumab (Total: 100 mg/kg; once weekly for 2 weeks) increases in vivo survival in CLL mouse models^[1].
Ianalumab (10 mg/kg; once weekly for 6 weeks) is enhanced by Ibrutinib (HY-10997) through an ITAM function on NK cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

115650  [NCBI]

Q96RJ3

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.44 kDa

1929549-92-7

Liquid

Colorless to light yellow

[Ianalumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Human BAFFR / TNFRSF13C, Fc Tag can bind Ianalumab. The EC₅₀ for this effect is 10.75 ng/mL.
• 
  Flow Cytometry analysis of Raji cells labelling TNFRSF13C/BAFFR/CD268 (red) with Ianalumab (anti-TNFRSF13C/BAFFR/CD268) (HY-P99653). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.

• [1]. McWilliams EM, et al. Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood Adv. 2019 Feb 12;3(3):447-460.  [Content Brief]